Trends in Antimicrobial Resistance in Gaza Strip, 2020–2022: Retrospective Study

Hashem M. Mansour^{*, 1}, Rana A. Kurraz², Ahmed Al Rabii³, Khalil I. Masood⁴

¹MSc clinical pharmacist, Indonesian Hospital-Gaza, Palestine

²Ph.D. Medical doctor, Indonesian Hospital-Gaza strip, Palestine

³Ph.D. Medical doctor, Indonesian Hospital-Gaza strip. Palestine

⁴GP in I.C.U department Indonesian Hospital-Gaza strip, Palestine

*Corresponding author: Hashem M. Mansour. MSc clinical pharmacist, Indonesian Hospital-Gaza, Palestine

Received: 04 August 2023; Accepted: 16 August 2023; Published: 30 August 2023

Key message:

The trend of bacterial resistance in the Gaza strip were unknown. The results of this study reveals increased incidence of bacterial infection by the mentioned bacteria and increased resistance to the mentioned drugs in this study. The importance of this study increase awareness to bacterial resistance and construction of antibiotic stewardship.

1. Introduction

The emergence of antimicrobial-resistant strains is increasing worldwide [1]. It results from the overuse of these agents among humans and animals [2]. Antibiotic resistance occurs when infectious bacterial strains survive after exposure to inappropriate antibiotics [3]. According to World Health Organization (WHO) predictions, if antibiotic resistance continues to increase, infectious diseases will become the most common cause of death worldwide [4]. In hospital care, the Germany review has discovered that the proportion of MRSA isolates showed a declining pattern, while the indicator of ESBL in E. coli shows an increasing trend. In addition, K. pneumoniae infections were found to be more frequent. [5]. In another review, there was increased resistance to carbapenems and aminoglycosides among some hospitals in Germany [6]. Based on the data from southern and eastern Europe, the carbapenem-resistant Acinetobacter spp. is high. [7]. In Saudi Arabia, the prevalence of MDR A. baumannii resistance to colistin and tigecycline has been reported to be high in many hospitals [8, 9].

Based on a systematic analysis, E. coli, followed by S. aureus, K. pneumoniae, S. pneumoniae, A. baumannii, and P. aeruginosa, are the leading pathogens for deaths associated with resistance [10]. In Thailand, the 30-day mortality rate caused by multidrug-resistant bacteremia was elevated and was high [11]. Regarding some bacteria, antimicrobial resistance remains unchanged or decreases in many countries, while other countries show an increase [12]. Based on the available data, some reports suggest that by 2050, nearly 10 million people will die annually due to antimicrobial-resistant strains. [13]. The results from this effort will contribute to the assessment of the burden of anti-microbial resistance (AMR) and provide essential health intelligence to guide interventions and policies for measuring the impact of interventions on future burdens [14]. Multidisciplinary approaches across healthcare sectors, in addition to developing novel strategies to fight these pathogens such as probiotics, vaccines, and antibiotic stewardship, will help to solve this problem [15, 16]. Several studies conducted in the Gaza Strip revealed increased multidrug bacterial resistance, even against carbapenems and colistin [17, 18].

This study aims to evaluate the bacterial resistance in the Gaza Strip and compare with that in other countries.

2. Methods

This study was conducted retrospectively in the Indonesian and Shifa hospitals in the Gaza Strip of Palestine. The data were collected from the electronic database by a clinical pharmacist. All cultures were recorded, including bacteria and antibiotic sensitivity based on the culture's results. No additional clinical specimens were obtained for research purposes; therefore, informed consent was not required. Data concerning antibiotic culture and sensitivity in the hospital were collected between January 2020 and November 2022. The study was approved by the Helsinki Committee (PHRC/HC/1205/22).

Bacterial isolates, including K. pneumonia, E. coli strains, Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter, were considered seriously. Susceptibility testing, detection of bacterial culture and sensitivity, including ESBL, and determination of minimum inhibitory concentrations were done on amikacin, vancomycin, colistin, piperacillin/tazobactam, meropenem, and ceftazidime for the previously mentioned bacteria. Data on colistin resistance for 2017 were not reported by the European Committee on Antimicrobial Susceptibility Testing's (EUCAST) warning concerning the results of susceptibility testing [19]. Data on population size was taken from the World Bank [20].

2.1 Statistical Analysis

All categorized variables were analyzed using percentages using SPSS v. 23. We calculate the percentage of each specimen, for each type of bacterial isolate, and the bacterial sensitivity to the antibiotic. We tested for significant changes over time in bloodstream infection (BSI) incidence using the Chi square test to compare between means. P- value less than 0.05 was considered statistically significant. The antibiotics are categorized as sensitive (S), intermediate (I), and resistant (R) based on their ability to inhibit bacterial growth. Here we focused on the resistant strains, so they were only mentioned in our surveillance.

3. Results

Table 1: Incidence per 100000 population and percent resistant to each anti biotic.

Table 2: Mean change in the resistance to the mentioned antibiotics

Data on the incidence of bloodstream infection (BSI) and the proportion of resistant isolates are presented in the tables above. The following trends were observed:

1. An increase in the incidence of all Acinetobacter baumannii infections (8.7 to 16.5 per 100,000 populations, p < 0.001) and the incidence of carbapenem-resistant A. baumannii (decreased 4%, p = 0.4, not significant), while the proportion of A. baumannii isolates resistant to carbapenems remained stable at70–80%.
2. An increase in the incidence of all Escherichia coli BSI (65.6 to 81.7 per 100,000 populations, p < 0.04) and amikacine-resistant E. coli BSI (13.7% to 32.4%, p < 0.001). The proportion of E. coli isolates with resistance to ceftazidime decreased by 1.5% (p = 0.07), fluoroquinolones and carbapenem increased to 28% and 63%, respectively(p<0.001).
3. There is a decrease in the incidence of all Klebsiella pneumoniae BSI (55.6 to 51.9 per 100,000 populations, p = 0.05), while carbapenem-resistant K. pneumoniae BSI increased (22.2% to 25.5% p = 0.001). The proportion of K. pneumoniae isolates with resistance to ceftazidime decreased from 62 to 57.1%(p=0.06).
4. The incidence of Pseudomonas aeruginosa BSI increased from 26.7 to 28.6 per 100,000 populations, p < 0.23, while the incidence of carbapenem-resistant P. aeruginosa increased from 12.5 to 19.6. The observed increase in carbapenem-resistant isolates did not achieve statistical significance (p = 0.07).
5. The incidence of all Staphylococcus aureus BSI increased, from 29.7 to 38.1 per 100,000 populations (p < 0.001). The incidence of BSI caused by methicillin-resistant S. aureus (MRSA) increased from 15% to 23% (p = 0.001).
6. There is a significant increase in the incidence of bacterial resistance to all the mentioned antibiotics (p < 0.05) except for ceftazidime; there is no significant decrease (p = 0.07), see Table 2.

4. Discussion

Between 2020 and 2022, the incidence of BSI caused by most antibiotic-resistant organisms significantly increased in Gaza-Strip except for ceftazidime, which decreased. The underlying cause is unknown but may be due to decreased use of this antibiotic in the last two years. It is worth mentioning that resistance proportions were higher than those observed in neighboring countries, southern Europe, and the United States of America. Despite the outbreak of third-generation cephalosporin and ciprofloxacin-resistant strains in the Gaza Strip, no national intervention was implemented to combat this problem. The absence of intervention will result in increased bacterial resistance, even to carbapenems and other wide-spectrum antibiotics, as mentioned above. This failure should catalyze the construction of a national-wide infection control (IC) program that should perform annual surveillance of antimicrobial susceptibility. It should include the establishment of a central reference laboratory, the creation of a national antibiotic stewardship program, and the enhancement of IC programs within healthcare centers and universities to increase awareness and overcome this problem. These actions will enhance the trends toward decreasing the emergence of antibiotic-resistant organisms reported here.

Our report has a number of limitations. Firstly, it was conducted in two hospitals, which means that the data cover nearly 70% of the Gaza Strip. In addition, we did not differentiate between community-acquired and hospital-acquired infections. Thus, it is predicted that the resistance to hospital-acquired infections may be higher than the one reported here. Moreover, we faced a lack of a national standard for reporting antimicrobial susceptibility. Although most microbiology laboratories in the Gaza Strip employ Clinical and Laboratory Standards Institute (CLSI) breakpoints, it is possible that for certain antibiotic categories, CLSI breakpoints are higher than those issued by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Levels of antimicrobial resistance, as we reported, are lower than they would be utilizing EUCAST criteria.

As noted above, the absence of interventions against bacterial resistance resulted in an increase in the proportion of carbapenem-resistant K. pneumoniae infections from 22.2% in 2020 to 25.3% two years later, explaining the difference in the proportion of carbapenem-resistant K. pneumoniae infections between Gaza and other southern countries. Our data and previous university studies in Gaza indicate an increase in the incidence of bloodstream infections due to colistin and extended-spectrum beta-lactamase (ESBL)-producing bacteria. The use of targeted control efforts against ESBL has been cited as one factor explaining the limited spread of ESBL in other countries, like Europe, as compared with ESBL-producing bacteria.

An important difference in the epidemiology of ESBL-producing and carbapenem-resistant Gram-negative bacteria is the role of asymptomatic carriers in the community. Carbapenem resistance is primarily hospital acquired (nosocomial), with little to no transmission in the community. These carriers serve as a major reservoir for infections with ESBL-producing bacteria in hospitals, implying that interventions limit the success of controlling the spread of these organisms. In Gaza, due to the absence of planned intervention, the combined incidence of BSI with typically hospital-acquired antibiotic-resistant organisms increased at the same time that the incidence of ESBL-producing E. coli BSI rose. Ongoing efforts are necessary to further inhibit the spread of resistant organisms, including the development of interventions aimed at community settings. Our study is strong because it contains real-world data from a large number of specimens. Also, it is the first study conducted in the Gaza Strip that compares antibiotic resistance between two periods.

5. Conclusion

These results showed increased trends to bacterial resistance except for ceftazidime. A specialist in clinical microbiology should take an active role in prescribing antibiotics in hospitals based on laboratory and epidemiological data besides clinical experience. Also, antibiotic stewardship should be constructed and activated in our country to control AB use even in the outpatient clinic, as this will decrease the emergence of resistant strains and decrease the burden.

Acknowledgements

We thank all of the healthcare institutions and personnel who contributed to the antimicrobial resistance data summarized and analyzed in this report.

Funding

None.

Abbreviations

WHO: world health organization. MDR: multi drug resistance. AMR: anti-microbial resistance. MRSA: methicillin resistant staph aureus. EUCAST: European Committee on Antimicrobial Susceptibility Testing's. IC: infection control. ESBL: extended-spectrum beta-lactamase. CLSI : Clinical and Laboratory Standards Institute. R: resistant. I: intermediate. S: sensitive.

Availability of data and materials

The datasets generated from the ministry of health –Gaza Strip.

Authors’ contributions

Hashem: Main author, the conception and design of the study, writing and  final approval of the version to be submitted. Khalil:  proofreading, Analysis and interpretation of data. Rana and Ahmed: Data collection and drafting the article for important intellectual content.

All authors read and approved the final manuscript.

Ethics approval and consent to participate

Publication was approved by the Palestine Ministry of Health. As per MoH policy, the article, which reports national aggregated data, publically available on the MoH, was not subject to ethics committee approval.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Sosa A de J Byarugaba DK Amabile C Hsueh PR Kariuki S Okeke IN (Eds). Springer, NY, USA (2010) Antimicrobial Resistance in Developing Countries.
2. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2017 2018 (2018).
3. Centers for Disease Control and Prevention About Antimicrobial Resistance (2018).
4. O’Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations (2014).
5. Noll, B Schweickert, M Abu Sin, M Feig, H Claus, T Eckmanns Antimicrobial resistance in Germany. Four years of antimicrobial resistance surveillance (ARS) 55 (2012): 1370-6.
6. Jane Hecht, Jessica Eisfeld, Jonathan HJ Baum, Christiane Wagner-Wiening, Daniela Leuze, Yulia Zimnitskaya, et al. An Outbreak of Carbapenem-Resistant Acinetobacter baumannii in Multiple Federal States in Germany Dtsch Arztebl Int 119 (2022): 508–509.
7. Olaniyi Ayobami, Niklas Willrich, Beneditta Suwono, Tim Eckmanns. Robby Markwart The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-Net data from 2013 to 2017. Antimicrob Resist Infect Control 19 (2020): 89.
8. Mutasim E Ibrahim Prevalence of Acinetobacter baumannii in Saudi Arabia: risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance Clin Microbiol Antimicrob 18 (2019): 1.
9. Aljindan R, Bukharie H, Alomar A, Abdalhamid B. Prevalence of digestive tract colonization of carbapenem-resistant Acinetobacter baumannii in hospitals in Saudi Arabia J Med Microbiol 64 (2015): 400-406.
10. Dr Mohsen Naghavi Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis Lancet 399 (2022): 629–655.
11. Cherry Lim, Emi Takahashi, Maliwan Hongsuwan, Vanaporn Wuthiekanun, Visanu Thamlikitkul, Soawapak Hinjoy, Nicholas PJ Day, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country eLife 5 (2016).
12. Yaakov Dickstein, Elizabeth Temkin, Michal Ish Shalom, David Schwartz, Yehuda Carmeli, and Mitchell J. Schwaber, Trends in antimicrobial resistance in Israel, 2014–2017 Antimicrob Resist Infect Control 8 (2019): 96.
13. Marlieke EA, de Kraker, Andrew J. Stewardson, and Stephan Harbarth Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLoS Med 13 (2016): e1002184.
14. Simon I Hay, Puja C Rao, Christiane Dolecek, Nicholas PJ Day, Andy Stergachis, Alan D Lopez, and et al. Measuring and mapping the global burden of antimicrobial resistance BMC Med 16 (2018): 78.
15. Bilal Aslam, Wei Wang, Muhammad Imran Arshad, Mohsin Khurshid, Saima Muzammil, Muhammad Hidayat Rasool, et al. Antibiotic resistance: a rundown of a global crisis Infect Drug Resist 11 (2018): 1645–1658.
16. Mohamed Abd El-Gawad El-Sayed Ahmed,Lan-Lan Zhong, Cong Shen, Yongqiang Yang. Yohei Doi, Guo-Bao Tian Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) Emerging Microbes & Infections 9 (2020): 868-885
17. European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST warnings concerning antimicrobial susceptibility testing products or procedures.
18. Abdelraouf A. Elmanama, Noor E. S. Abu Tayyem, Isabella Sjà lander Antimicrobial resistance of bacterial isolates from the clinical and hospital environment in Gaza Strip, Palestine The International Arabic Journal of Antimicrobial Agents: A review over 20-year 11 (2021).
19. Hashem M Mansour, Rana A Kurraz, Ahmed Al Rabii, Khalil I Masood. Haytham Nassar. Prevalence Of Bacterial Resistance to Colistin, Meropenem, Piperacillin-tazobactam, Ceftazidime, Vancomycin And Amikacin Antibiotics Based On Culture And Sensitivity In The Indonesian And Shifa Hospitals In Palestine: A Retrospective Study British journal of medical and health science 5 (2023).
20. The World Bank Group (2019).